Get started
Author

Kathy Puvana Theall

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
2021 · Michael Gnant, Amylou C. Dueck, et al. · Journal of Clinical Oncology · 235
PDF
Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study
2009 · William M. Sikov, Don S. Dizon, et al. · Journal of Clinical Oncology · 108
PDF
A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma
2011 · Olga N. Kozyreva, Dorcas Chi, et al. · The Oncologist · 37
PDF
Weekly Paclitaxel and Carboplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
2011 · Neal E. Ready, Ritesh Rathore, et al. · American Journal of Clinical Oncology · 23
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
2025 · A. DeMichele, A. C. Dueck, et al. · Breast Cancer Research · 4
PDF
Abstract PO2-05-04: ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
2024 · Hope Rugo, Aditya Bardia, et al. · Cancer Research · 4
Phase II study of induction weekly paclitaxel, ifosfamide, and carboplatin (PIC) followed by chemoradiotherapy (CRT) in locally advanced head and neck squamous cell cancer (HNSCC): A Brown University Oncology Group study (HN-86)
2005 · R. Rathore, P. Chougule, et al. · Journal of Clinical Oncology · 4
Abstract PO2-05-05: ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
2024 · Nuhad Ibrahim, Sung-Bae Kim, et al. · Cancer Research · 3
1815 A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes
2015 · N. Harbeck, M. Cristofanilli, et al. · European Journal of Cancer · 3
Gemcitabine and capecitabine in metastatic breast cancer (MBC): A Brown University Oncology Group (BrUOG) phase II study
2005 · W. M. Sikov, K. P. Theall, et al. · Journal of Clinical Oncology · 3
Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial
2022 · Michael Gnant, Amylou C Dueck, et al. · Cancer Research · 1
Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis
2020 · Richard S Finn, Hope S Rugo, et al. · Cancer Research · 1
Efficacy and Safety of Palbociclib Plus Endocrine Therapy (ET) for HR+/HER2-Advanced Breast Cancer (ABC) in the Asian-Pacific (AP) Region
2018 · Im, S-A, Masuda, N., et al. · UWA Profiles and Research Repository (UWA)
A multicenter retrospective study on clinical features and outcome in elderly patients with hepatocellular carcinoma.
2010 · O. N. Kozyreva, D. Chi, et al. · Journal of Clinical Oncology
Works count: 14
Citation count: 426
H-index: 4
I10-index: 4
Year
Topic
Type